Skip to main content
Erschienen in: Lung 1/2017

13.10.2016

Prognostic Impact of Node-Spreading Pattern in Surgically Treated Small-Cell Lung Cancer: A Multicentric Analysis

verfasst von: Giovanni Leuzzi, Filippo Lococo, Gabriele Alessandrini, Isabella Sperduti, Lorenzo Spaggiari, Federico Venuta, Erino A. Rendina, Pierluigi M. Granone, Cristian Rapicetta, Piero Zannini, Gaetano Di Rienzo, Maurizio Nicolosi, Francesco Facciolo

Erschienen in: Lung | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Abstract

Objective

Although surgery in selected small-cell lung cancer (SCLC) patients has been proposed as a part of multimodality therapy, so far, the prognostic impact of node-spreading pattern has not been fully elucidated. To investigate this issue, a retrospective analysis was performed.

Methods

From 01/1996 to 12/2012, clinico-pathological, surgical, and oncological features were retrospectively reviewed in a multicentric cohort of 154 surgically treated SCLC patients. A multivariate Cox proportional hazard model was developed using stepwise regression, in order to identify independent outcome predictors. Overall (OS), cancer-specific (CSS), and Relapse-free survival (RFS) were calculated by Kaplan-Meier method.

Results

Overall, median OS, CSS, and RFS were 29 (95 % CI 18–39), 48 (95 % CI 19–78), and 22 (95 % CI 17–27) months, respectively. Lymphadenectomy was performed in 140 (90.9 %) patients (median number of harvested nodes: 11.5). Sixty-seven (47.9 %) pN0-cases experienced the best long-term survival (CSS: 71, RFS: 62 months; p < 0.0001). Among node-positive patients, no prognostic differences were found between pN1 and pN2 involvement (CSS: 22 vs. 15, and RFS: 14 vs. 10 months, respectively; p = 0.99). By splitting node-positive SCLC according to concurrent N1-invasion, N0N2-patients showed a worse CSS compared to those cases with combined N1N2-involvement (N0N2: 8 months vs. N1N2: 22 months; p = 0.04). On the other hand, the number of metastatic stations (p = 0.80) and the specific node-level (p = 0.85) did not affect CSS. At multivariate analysis, pN+ (HR: 3.05, 95 % CI 1.21–7.67, p = 0.02) and ratio between metastatic and resected lymph-nodes (RL, HR: 1.02, 95 % CI 1.00–1.04, p = 0.03) were independent predictors of CSS. Moreover, node-positive patients (HR: 3.60, 95 % CI 1.95–6.63, p < 0.0001) with tumor size ≥5 cm (HR: 1.85, 95 % CI 0.88–3.88, p = 0.10) experienced a worse RFS.

Conclusions

In selected surgically treated SCLC, the long-term survival may be stratified according to the node-spreading pattern.
Literatur
1.
Zurück zum Zitat Riaz S, Luchtenborg M, Coupland VB et al (2012) Trends in incidence of small cell lung cancer and all lung cancer. Lung Cancer 75:280–284CrossRefPubMed Riaz S, Luchtenborg M, Coupland VB et al (2012) Trends in incidence of small cell lung cancer and all lung cancer. Lung Cancer 75:280–284CrossRefPubMed
2.
Zurück zum Zitat Lassen U, Osterlind K, Hansen M et al (1995) Long-term survival in small-cell lung cancer: posttreatment characteristics in patients surviving 5 to 18+ years–an analysis of 1,714 consecutive patients. J Clin Oncol. 13(5):1215–1220PubMed Lassen U, Osterlind K, Hansen M et al (1995) Long-term survival in small-cell lung cancer: posttreatment characteristics in patients surviving 5 to 18+ years–an analysis of 1,714 consecutive patients. J Clin Oncol. 13(5):1215–1220PubMed
3.
Zurück zum Zitat Sawabata N, Miyaoka E, Asamura H et al (2011) Japanese Lung Cancer Registry Study of 11,663 surgical cases in 2004: demographic and prognosis changes over decade. J Thorac Oncol 6:1229–1235CrossRefPubMed Sawabata N, Miyaoka E, Asamura H et al (2011) Japanese Lung Cancer Registry Study of 11,663 surgical cases in 2004: demographic and prognosis changes over decade. J Thorac Oncol 6:1229–1235CrossRefPubMed
4.
Zurück zum Zitat Govindan R, Page N, Morgensztern D et al (2006) Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol. 24(28):4539–4544CrossRefPubMed Govindan R, Page N, Morgensztern D et al (2006) Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol. 24(28):4539–4544CrossRefPubMed
5.
Zurück zum Zitat Combs SE, Hancock JG, Boffa DJ et al (2015) Bolstering the case for lobectomy in stages I, II, and IIIA small-cell lung cancer using the National Cancer Data Base. J Thorac Oncol. 10(2):316–323CrossRefPubMed Combs SE, Hancock JG, Boffa DJ et al (2015) Bolstering the case for lobectomy in stages I, II, and IIIA small-cell lung cancer using the National Cancer Data Base. J Thorac Oncol. 10(2):316–323CrossRefPubMed
6.
Zurück zum Zitat Hara N, Ohta M, Ichinose Y et al (1991) Influence of surgical resection before and after chemotherapy on survival in small cell lung cancer. J Surg Oncol 47:53–61CrossRefPubMed Hara N, Ohta M, Ichinose Y et al (1991) Influence of surgical resection before and after chemotherapy on survival in small cell lung cancer. J Surg Oncol 47:53–61CrossRefPubMed
7.
Zurück zum Zitat Shepherd FA, Evans WK, Feld R et al (1988) Adjuvant chemotherapy following surgical resection for small-cell carcinoma of the lung. J Clin Oncol 6:832–838PubMed Shepherd FA, Evans WK, Feld R et al (1988) Adjuvant chemotherapy following surgical resection for small-cell carcinoma of the lung. J Clin Oncol 6:832–838PubMed
8.
Zurück zum Zitat Badzio A, Kurowski K, Karnicka-Mlodkowska H et al (2004) A retrospective comparative study of surgery followed by chemotherapy vs. non-surgical management in limited-disease small cell lung cancer. Eur J Cardiothorac Surg 26(1):183–188CrossRefPubMed Badzio A, Kurowski K, Karnicka-Mlodkowska H et al (2004) A retrospective comparative study of surgery followed by chemotherapy vs. non-surgical management in limited-disease small cell lung cancer. Eur J Cardiothorac Surg 26(1):183–188CrossRefPubMed
9.
Zurück zum Zitat Edge SB, Byrd DR, Compton CC, et al (eds) (2010) AJCC-Cancer Staging Manual, 7th edn. Springer, Chicago, pp 299–323 Edge SB, Byrd DR, Compton CC, et al (eds) (2010) AJCC-Cancer Staging Manual, 7th edn. Springer, Chicago, pp 299–323
10.
Zurück zum Zitat Travis WD, Brambilla E, Muller-Hermelink HK (2004) World Health Organization classification of tumours: pathology and genetics of tumours of the lung, pleura, thymus and heart. IARC Press, Lyon Travis WD, Brambilla E, Muller-Hermelink HK (2004) World Health Organization classification of tumours: pathology and genetics of tumours of the lung, pleura, thymus and heart. IARC Press, Lyon
11.
Zurück zum Zitat Fox W, Scadding JG (1973) Medical Research Council comparative trial of surgery and radiotherapy for the primary treatment of small-celled or oat-celled carcinoma of the bronchus: ten-year follow-up. Lancet 2:63–65CrossRefPubMed Fox W, Scadding JG (1973) Medical Research Council comparative trial of surgery and radiotherapy for the primary treatment of small-celled or oat-celled carcinoma of the bronchus: ten-year follow-up. Lancet 2:63–65CrossRefPubMed
12.
Zurück zum Zitat Lad T, Piantadosi S, Thomas P et al (1994) A prospective randomized trial to determine the benefit of surgical resection of residual disease following response of small cell lung cancer to combination chemotherapy. Chest 106:320–323CrossRef Lad T, Piantadosi S, Thomas P et al (1994) A prospective randomized trial to determine the benefit of surgical resection of residual disease following response of small cell lung cancer to combination chemotherapy. Chest 106:320–323CrossRef
13.
Zurück zum Zitat Jett JR, Schild SE, Kesler KA, et al. (2013) Treatment of small cell lung cancer: Diagnosis and management of lung cancer, 3rd edn. American College of Chest Physicians evidence-based clinical practice guidelines. Chest 143 (5 Suppl):e400S-19S Jett JR, Schild SE, Kesler KA, et al. (2013) Treatment of small cell lung cancer: Diagnosis and management of lung cancer, 3rd edn. American College of Chest Physicians evidence-based clinical practice guidelines. Chest 143 (5 Suppl):e400S-19S
14.
Zurück zum Zitat Inoue M, Miyoshi S, Yasumitsu T et al (2000) Surgical results for small cell lung cancer based on the new TNM staging system. Ann Thorac Surg 70:1615–1619CrossRefPubMed Inoue M, Miyoshi S, Yasumitsu T et al (2000) Surgical results for small cell lung cancer based on the new TNM staging system. Ann Thorac Surg 70:1615–1619CrossRefPubMed
15.
Zurück zum Zitat Miyamoto M, Morikawa T, Kaga K et al (2006) Subcarinal node is the significant node that affects survival in resected small cell lung cancer. Surg Today 36(8):671–675CrossRefPubMed Miyamoto M, Morikawa T, Kaga K et al (2006) Subcarinal node is the significant node that affects survival in resected small cell lung cancer. Surg Today 36(8):671–675CrossRefPubMed
16.
Zurück zum Zitat Bria E, Milella M, Sperduti I et al (2009) A novel clinical prognostic score incorporating the number of resected lymph-nodes to predict recurrence and survival in non-small-cell lung cancer. Lung Cancer. 66(3):365–371CrossRefPubMed Bria E, Milella M, Sperduti I et al (2009) A novel clinical prognostic score incorporating the number of resected lymph-nodes to predict recurrence and survival in non-small-cell lung cancer. Lung Cancer. 66(3):365–371CrossRefPubMed
17.
Zurück zum Zitat Legras A, Mordant P, Arame A et al (2014) Long-term survival of patients with pN2 lung cancer according to the pattern of lymphatic spread. Ann Thorac Surg. 97(4):1156–1162CrossRefPubMed Legras A, Mordant P, Arame A et al (2014) Long-term survival of patients with pN2 lung cancer according to the pattern of lymphatic spread. Ann Thorac Surg. 97(4):1156–1162CrossRefPubMed
18.
Zurück zum Zitat Naruke T, Suemasu K, Ishikawa S (1978) Lymph node mapping and curability at various levels of metastasis in resected lung cancer. J Thorac Cardiovasc Surg 76(6):832–839PubMed Naruke T, Suemasu K, Ishikawa S (1978) Lymph node mapping and curability at various levels of metastasis in resected lung cancer. J Thorac Cardiovasc Surg 76(6):832–839PubMed
19.
Zurück zum Zitat Kobayashi S, Okada S, Hasumi T et al (2000) The significance of surgery for bulky N2 small-cell lung cancer: a clinical and in vitro analysis of long-term survivors. Surg Today 30(11):978–986CrossRefPubMed Kobayashi S, Okada S, Hasumi T et al (2000) The significance of surgery for bulky N2 small-cell lung cancer: a clinical and in vitro analysis of long-term survivors. Surg Today 30(11):978–986CrossRefPubMed
20.
Zurück zum Zitat Inoue M, Nakagawa K, Fujiwara K et al (2000) Results of preoperative mediastinoscopy for small cell lung cancer. Ann Thorac Surg 70:1620–1623CrossRefPubMed Inoue M, Nakagawa K, Fujiwara K et al (2000) Results of preoperative mediastinoscopy for small cell lung cancer. Ann Thorac Surg 70:1620–1623CrossRefPubMed
21.
Zurück zum Zitat Vallieres E, Shepherd FA, Crowly J et al (2009) The IASLC proposals regarding the pathologic staging of small cell lung cancer in forthcoming (seventh) edition of the tumor, node, metastasis classification for lung cancer. J Thorac Oncol. 4:1049–1059CrossRefPubMed Vallieres E, Shepherd FA, Crowly J et al (2009) The IASLC proposals regarding the pathologic staging of small cell lung cancer in forthcoming (seventh) edition of the tumor, node, metastasis classification for lung cancer. J Thorac Oncol. 4:1049–1059CrossRefPubMed
22.
Zurück zum Zitat Wada H, Nakajima T, Yasufuku K et al (2010) Lymph node staging by endobronchial ultrasound- guided transbronchial needle aspiration in patients with small cell lung cancer. Ann Thorac Surg 90:229–234CrossRefPubMed Wada H, Nakajima T, Yasufuku K et al (2010) Lymph node staging by endobronchial ultrasound- guided transbronchial needle aspiration in patients with small cell lung cancer. Ann Thorac Surg 90:229–234CrossRefPubMed
Metadaten
Titel
Prognostic Impact of Node-Spreading Pattern in Surgically Treated Small-Cell Lung Cancer: A Multicentric Analysis
verfasst von
Giovanni Leuzzi
Filippo Lococo
Gabriele Alessandrini
Isabella Sperduti
Lorenzo Spaggiari
Federico Venuta
Erino A. Rendina
Pierluigi M. Granone
Cristian Rapicetta
Piero Zannini
Gaetano Di Rienzo
Maurizio Nicolosi
Francesco Facciolo
Publikationsdatum
13.10.2016
Verlag
Springer US
Erschienen in
Lung / Ausgabe 1/2017
Print ISSN: 0341-2040
Elektronische ISSN: 1432-1750
DOI
https://doi.org/10.1007/s00408-016-9954-4

Weitere Artikel der Ausgabe 1/2017

Lung 1/2017 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.